Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.


Bank Name Mirati Therapeutics, Inc.
Stock Exchange NASDAQ
Symbol MRTX
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
Chairman Dr. Charles M. Baum
CEO Dr. Rodney W. Lappe
Employees 51
Website www.mirati.com
Registered Year